# Intra-nasal vs. Intra-venous Ketamine Administration

> **NCT02644629** · PHASE4 · COMPLETED · sponsor: **Shalvata Mental Health Center** · enrollment: 45 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ketamine (1st phase)
- **DRUG:** Ketamine (2st phase)

## Key facts

- **NCT ID:** NCT02644629
- **Lead sponsor:** Shalvata Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2020-05
- **Final completion:** 2020-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644629, "Intra-nasal vs. Intra-venous Ketamine Administration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02644629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*